UK markets closed

Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
108.17-0.87 (-0.80%)
At close: 1:00PM EST
106.02 -2.15 (-1.99%)
After hours: 03:48PM EST
Full screen
Trade prices are not sourced from all markets
Previous close109.04
Bid106.02 x 1200
Ask110.40 x 900
Day's range108.02 - 109.05
52-week range66.59 - 115.95
Avg. volume914,374
Market cap246.748B
Beta (5Y monthly)0.26
PE ratio (TTM)35.92
EPS (TTM)3.01
Earnings dateN/A
Forward dividend & yield1.47 (1.36%)
Ex-dividend date16 Aug 2021
1y target est116.10
  • Reuters

    Novo Nordisk says lower insulin prices in China dent 2022 outlook

    Novo Nordisk on Friday forecast its sales growth would slow by about 3% in 2022 because of lower prices and a drop in insulin sales volumes in China, denting the Danish diabetes drug maker's share price. The forecast comes after Novo received results from China's Volume Based Procurement (VBP) tender, which covers insulin sold at Chinese hospitals. "Novo Nordisk currently expects an estimated negative impact on global sales growth of around 3% in 2022 as a result of reduced prices and reduced volumes of insulin sold in China," it said in a statement.

  • Globe Newswire

    Novo Nordisk announces impact from Volume Based Procurement for insulin in China

    Bagsværd, Denmark, 26 November 2021 – Novo Nordisk today announced that the company has received the results from the Volume Based Procurement (VBP) tender for insulin in China. The Chinese National Healthcare Security Administration has tendered insulin sold at hospitals, and Novo Nordisk has participated in the tender. All Novo Nordisk’s insulin were included in the tender except for Ryzodeg® and Xultophy®. Novo Nordisk currently expects an estimated negative impact on global sales growth of a

  • Motley Fool

    4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout

    The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.